Piper Sandler analyst Jason Bednar reiterated a Buy rating on Alpha Tau Medical Ltd (DRTS – Research Report) today and set a price target of $8.00. The company’s shares closed yesterday at $2.93.
Bednar covers the Healthcare sector, focusing on stocks such as Align Tech, Henry Schein, and Cooper Co. According to TipRanks, Bednar has an average return of -10.4% and a 33.66% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Alpha Tau Medical Ltd with a $13.33 average price target.
See the top stocks recommended by analysts >>
DRTS market cap is currently $203.6M and has a P/E ratio of -8.85.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alpha Tau Medical Ltd (DRTS) Company Description:
Alpha Tau is an Israel-based medical device company focusing on the research, development, and potential commercialization of the Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) for the treatment of solid tumors.
Read More on DRTS:
- Alpha Tau Medical Announces Third Quarter 2023 Financial Results and Provides Corporate Update
- Alpha Tau enters into long-term lease of site in New Hampshire
- Alpha Tau announces Hahn has joined its Scientific Advisory Board
- Alpha Tau Medical Ltd. Set for Major Advancements in Cancer Trials: A Comprehensive Overview of Ongoing Studies and Future Prospects
